KNX100
Agitation and aggression associated with dementia
Phase 2Active
Key Facts
Indication
Agitation and aggression associated with dementia
Phase
Phase 2
Status
Active
Company
About Kinoxis Therapeutics
Australian biotech leveraging ALOX15 inhibition for CNS agitation, pain, and substance‑use disorders.
View full company profile